At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 376 enrolled
Drug / intervention
GEn 1200mg/day +3 moredrug
Likely dose
GEn 1200mg/dayfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study PXN110748: An Efficacy and Safety Study of XP13512 Compared With a Concurrent Placebo Control in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN)
In Brief
A Phase 2 clinical trial evaluating GEn 1200mg/day, GEn 2400mg/day, and 2 other interventions for Neuralgia, Postherpetic. Completed, enrolled 376 participants across 83 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with post-herpetic neuralgia (PHN).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuralgia, Postherpetic
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2008
First PostedFeb 2008
Primary CompletionJul 2009
TodayJul 2026
First PostedFeb 21, 2008
Enrollment StartFeb 1, 2008
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 18.4 years ago
Interventions
GEn 1200mg/daydrug
gabapentin enacarbil 1200mg/day
GEn 2400mg/daydrug
gabapentin enacarbil 2400mg/day
GEn 3600mg/daydrug
gabapentin enacarbil 3600mg/day
Placebodrug
placebo